Affordable Insulin Now Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Affordable Insulin Now Act (H.R. 1488) is a health policy bill introduced in the 118th Congress aimed at addressing the cost of insulin. The bill was referred to the Subcommittee on Health but did not advance further and ultimately failed or expired. Specific provisions, full text, and detailed summary are not available in the source data, limiting detailed analysis of its mechanisms or scope.
H.R. 1488 sought to make insulin more affordable but did not progress beyond initial committee referral and expired without enactment.
- The bill is categorized under the Health policy area, indicating a focus on healthcare cost or access.
- It was introduced in the House of Representatives during the 118th Congress.
- The latest recorded action was referral to the Subcommittee on Health on December 17, 2024, with no further legislative movement.
['People who use insulin for diabetes management', 'Healthcare providers involved in diabetes care', 'Potentially health insurers and healthcare systems if insulin costs are regulated']
['Lack of available full text and summary limits understanding of implementation details and enforcement mechanisms', 'Unclear funding sources or cost implications for government programs or private insurers', 'Oversight and authority provisions are not specified, raising questions about enforcement and regulatory roles']
The bill was introduced in the 118th Congress and referred to a relevant health subcommittee but did not advance, indicating limited legislative momentum or prioritization during the session. The failure or expiration status reflects that it was not enacted into law during this Congress.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential reduction in out-of-pocket costs for insulin users if the bill had passed', 'Possible shifts in healthcare provider prescribing practices or insurance coverage policies', 'Economic impacts on pharmaceutical companies producing insulin due to pricing regulations']
The absence of full text and official summary limits transparency and public understanding of the bill's specific provisions and mechanisms. The bill's failure to advance beyond subcommittee referral suggests limited legislative support or prioritization. Oversight considerations remain unclear due to missing details on enforcement and funding.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.